Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 173

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 173
---
 |

| ● | Obtaining and leveraging government grants to fund project development. |

A significant portion of our financial resources have been used to
develop our Lead Projects. Our Lead Projects are ALS-4 and SACT-1. In March 2023, we announced that we completed the Pre-IND discussions
with the US FDA on ALS-4. In March 2023, we also announced the completion of the End of Phase 1 (EOP1) meeting of SACT-1 with the US FDA.
The FDA generally agreed with the chemistry-manufacturing-control (CMC) strategy and our proposed clinical development plan for SACT-1
Phase 1/2 trials. Currently, ALS-4 and SACT-1 are Phase 2 clinical trials ready.

<div align='center'>84</div>

During the second quarter
of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending work on non-lead products.
This measure is aimed at optimizing the allocation of our resources and focusing our efforts on advancing our lead projects, which hold
the most promise for commercial success and beneficial impact. This decision aligns with our commitment to enhance shareholder value and
effectively drive our core objectives forward in the competitive landscape.

Abandoned Merger

On March 1, 2024, we entered into an Agreement and Plan of Merger with
YOOV Group Holding Limited, a company organized under the laws of British Virgin Islands (“YOOV”), pursuant to which YOOV
was to become one of our wholly owned subsidiaries. However, on October 25, 2024, the parties to the Agreement and Plan of Merger entered
into a termination agreement (the “Termination Agreement”), pursuant to which the parties agreed to terminate the Agreement
and Plan of Merger on the date thereof, and such agreement became null and void and of no further force or effect.

Registered Direct Offering

On January 2, 2025, the Company
entered into a certain securities purchase agreement (the “Securities Purchase Agreement”) with certain non-affiliated institutional
investors pursuant to which the Company sold 1,535,000 Class A Ordinary Shares of the Company at a per share price of $2.00 in a registered
direct offering, for gross proceeds of $3,070,000 (the “RDO”).

Private Placement Offerings

On September 11, 2023, the
Company entered into a Securities Purchase Agreement with